Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Affinity and avidity in antibody-based tumor targeting.

Rudnick SI, Adams GP.

Cancer Biother Radiopharm. 2009 Apr;24(2):155-61. doi: 10.1089/cbr.2009.0627. Review.

2.

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP.

Cancer Res. 2011 Mar 15;71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277.

3.

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM.

Cancer Res. 2001 Jun 15;61(12):4750-5.

4.

Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model.

Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD.

Cancer Res. 2000 Dec 15;60(24):7008-13.

6.

Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK.

Q J Nucl Med. 1998 Dec;42(4):225-41. Review.

PMID:
9973838
7.

Direct binding of radioiodinated monoclonal antibody to tumor cells: significance of antibody purity and affinity for drug targeting or tumor imaging.

Kennel SJ, Foote LJ, Lankford PK, Johnson M, Mitchell T, Braslawsky GR.

Hybridoma. 1983;2(3):297-310.

PMID:
6678798
9.

The macroscopic and microscopic pharmacology of monoclonal antibodies.

Weinstein JN, van Osdol W.

Int J Immunopharmacol. 1992 Apr;14(3):457-63. Review.

PMID:
1618598
10.

Targeted drug delivery using immunoconjugates: principles and applications.

Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C.

J Immunother. 2011 Nov-Dec;34(9):611-28. doi: 10.1097/CJI.0b013e318234ecf5. Review.

PMID:
21989410
11.

Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.

Kuroki M, Hachimine K, Huang J, Shibaguchi H, Kinugasa T, Maekawa S, Kuroki M.

Anticancer Res. 2005 Nov-Dec;25(6A):3725-32. Review.

12.

Mixing two monoclonal antibodies yields enhanced affinity for antigen.

Ehrlich PH, Moyle WR, Moustafa ZA, Canfield RE.

J Immunol. 1982 Jun;128(6):2709-13.

PMID:
7077082
13.

Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.

Deyev SM, Lebedenko EN.

Bioessays. 2008 Sep;30(9):904-18. doi: 10.1002/bies.20805.

PMID:
18693269
14.

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH.

Cancer Res. 2000 Sep 15;60(18):5237-43.

15.

Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.

Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL.

Cancer Res. 1992 Jan 15;52(2):377-84.

16.

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.

Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM.

J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7.

17.

Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.

Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ.

Cancer Res. 2000 Aug 15;60(16):4475-84.

18.

Single-chain antibodies in pancreatic cancer.

Colcher D, Pavlinkova G, Beresford G, Booth BJ, Batra SK.

Ann N Y Acad Sci. 1999 Jun 30;880:263-80. Review.

PMID:
10415872
19.
20.

CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.

Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V.

Int J Cancer. 1993 May 28;54(3):418-25.

PMID:
8389737

Supplemental Content

Support Center